The effect of parathyroid hormone lowering by etelcalcetide therapy on calcification propensity and calciprotein particles in hemodialysis patients.

ABSTRACT:

Background

This study investigated whether parathyroid hormone (PTH) lowering with etelcalcetide, and the consequent effects on mineral and bone metabolism, could improve serum calcification propensity (T50 time) and decrease calciprotein particle (CPP) load in hemodialysis patients with secondary hyperparathyroidism.

Methods

In this single-arm, prospective, dose-escalation proof-of-principle study, hemodialysis patients received etelcalcetide at 2.5 mg/dialysis session with increments of 2.5 mg every 4 weeks to a maximum dose of 15 mg three times a week or until a pre-specified safety endpoint was reached, followed by an 8-week wash-out phase.

Results

Out of 36 patients recruited (81% male, 62 ± 13 years), 16 patients completed the study per protocol with a mean maxi

SUBMITTER: Thiem U 

PROVIDER: S-EPMC11197474 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature